How much revenue does Poniard Pharmaceuticals make?

Poniard Pharmaceuticals reported $0 in revenue for fiscal year 2010. In Q3 2011 revenue was $0.

What companies are similar to Poniard Pharmaceuticals?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include ForU Holdings, Inc. (FORU), Thoughtful Brands Inc. (PEMTF), Verde Science, Inc. (VRCI), NexImmune, Inc. (NEXI).

Poniard Pharmaceuticals, Inc. (PARD) Stock

About Poniard Pharmaceuticals, Inc.

Poniard Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of cancer therapeutics. Its lead platform product candidate includes Picoplatin, a platinum-based cancer therapy to treat multiple cancer indications, including small cell lung, colorectal, prostate, and ovarian cancers. The company has conducted a pivotal Phase III SPEAR trial of Picoplati...

At a glance

Poniard Pharmaceuticals reported revenue of $0 for fiscal year 2010, and net income of -$30.79 million. In Q3 2011 (the quarter ended September 30, 2011) revenue was $0.

Figures from company filings; latest fiscal year ended December 31, 2010.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.